Poor tumour recognition by T cells and T cell exhaustion are fundamental resistance mechanisms to current immuno-oncology therapy. Clinical data continues to demonstrate that tumours which are more visible, i.e. express greater numbers of neoantigens, to the immune system show improved responses to immune checkpoint inhibitors. Further, T cell exhaustion, caused by chronic antigen stimulation, also correlates with poorer outcomes across cancer types.

Grey Wolf has developed unique insights into the targeting of the ERAP enzymes and validated the role for ERAP inhibition in modulating the cancer-related antigen repertoire. These in-house data provide compelling evidence that the therapies could have a real impact in the treatment of oncology and overcoming these key resistance mechanisms. Grey Wolf combines first class drug discovery, in depth investigative biology, with biomarker discovery and development to guide efficient and focused clinical development. 

Discovery Preclinical Candidate Nomination IND/CTA enabling Phase I Phase II
  • Phase I
(follow on molecules)
  • IND/CTA enabling
  • Discovery
MHCI directed therapies
  • Discovery

The above information is accurate as of January 2023. The safety and efficacy of these investigation molecules is yet to be established. There is no guarantee that these molecules will proceed to market and become commercially available as these are agents in drug development could be terminated during the development process.